All Episodes

The RAPCHEM study's 10-year follow-up shows risk-based radiotherapy de-escalation after primary systemic therapy is safe for early breast cancer patients. Fleur Mauritz MD from MAASTRO presented these findings at EBCC 2026, demonstrating long-term safety of reduced radiation in select patients.

The LORD trial finds active surveillance is as effective as standard therapy for ER-positive, HER2-negative, grade 1–2 DCIS. Randomisation was stopped early due to reassuring results. Jelle Wesseling MD PhD from the Netherlands Cancer Institute presented the findings at EBCC 2026 in Barcelona.

Circulating tumour DNA outperforms clinical markers like pathological complete remission in predicting relapse after neoadjuvant therapy for early breast cancer. Elisa Agostinetto MD from Institut Jules Bordet presented this prospective pooled analysis from Belgium and Italy at EBCC 2026.

The OPBC-09 PRExRT study shows polyurethane-coated breast implants reduce capsular contracture risk vs uncoated implants after mastectomy with immediate pre-pectoral reconstruction and radiotherapy. Kerstin Wimmer MD from Medical University of Vienna presented the results at EBCC 2026 in Barcelona.

The OASIS-4 phase III trial shows elinzanetant, a dual neurokinin receptor antagonist, significantly reduces hot flashes in breast cancer patients on endocrine therapy. Fatima Cardoso MD from Centre Antoine Lacassagne in Nice reported rapid onset and sustained effects over 52 weeks at EBCC 2026.

BRAVE-HEART Study Shows How Breath-Holding System Halves Coronary Radiation Dose During Left Breast Irradiation An interview with: Elisabetta Bonzano MD PhD, IRCCS San Matteo Polyclinic Foundation, Ra

European Breast Cancer Conference: Focus on Therapy De-escalation and Individualization An interview with: Philip Poortmans MD PhD, Radiation Oncology Department, University of Antwerp & Iridium N

Molecular Test Distinguishes Ipsilateral Second Primary from Recurrent Breast Cancer An interview with: Tess Snellen MD, Netherlands Cancer Institute – Antoni van Leeuwenhoek hospital, Departmen

Antibody Drug Conjugate T-DXd Brings Longer Cancer-Free Survival for Patients with HER2-Positive Early Breast Cancer and Residual Invasive Disease An interview with: Charles E Geyer MD, Breast Medical

Hope S. Rugo, MD; SABCS 2025: Selective Estrogen Degrader Giredestrant Brings Clinically Meaningful Improvements in Metastatic Breast Cancer: evERA Breast Cancer Trial An interview with: Hope S. Rugo,

Othman Al-Sawaf MD PhD; ASH 2025: Fixed-Duration Targeted Combinations As Effective as Extended Monotherapy for Patients with Untreated Chronic Lymphocytic Leukemia An interview with: Othman Al-Sawaf

Juan Du MD PhD,  ASH 2025: Dual Targeted FasTCAR-T Therapy brings Deep, Durable Responses to Patients with Newly Diagnosed Multiple Myeloma An interview with: Juan Du MD PhD, Ren Ji Hospital, Shanghai

Breast cancer staging: neoadjuvant chemotherapy benefits

relapsed/refractory multiple myeloma bi-specific antibody: big benefits

Erika Hamilton MD; 2025 SABCS: Small Molecule HER2 Inhibitor Tucatinib Improves Progression Free Survival in Patients with HER2-positive Metastatic Breast Cancer: in HER2CLIMB-05 Trial An interview wi

Wojciech Jurczak MD PhD; ASH 2025: Big Study Suggests Non-Covalent BTK Inhibitor Pirtobrutinib Could be New Standard-of-Care for Patients with Untreated Chronic Lymphocytic Leukemia An interview with:

Improved Responses to Anti-PD-1 immune therapy and chemotherapy could result from neoadjuvant radiation therapy for invasive luminal breast cancer

Gentler therapy for AML in young fit patients had better outcomes compared to standard induction chemotherapy

Non-Covalent BTK Inhibitor First in CLL: Less Toxic, As Effective as Covalent

Healthy eating could be a key to breast cancer treatment success: microbiome influence in immunotherapy outcomes identified,

The donor pool for allogeneic stem cell transplantation could be greatly increased, improving access to transplant for minorities who are currently excluded for transplantation according to findings of this big American study.

Oncoplastic breast conserving surgery for breast cancer is practical, effective and very desirable in low and middle income country settings, new research study finds.

Luciano Costa MD PhD ASH 2025

Aromatase inhibitor adjuvant hormone therapy for women with ER+ HER2- early breast cancer performed better than adjuvant treatment with a selective estrogen receptor modifier such as tamoxifen

Hisham Abdel-Azim MD MS

A seective estrogen degrader out-performed AI's in ER+ HER- early breast cancer

Financial Disaster from curative treatment for childhood ALL

Dramatic Cures for Children with No Prospects Using Standard Therapies for T-cell malignancies

Some patients being treated for stage three colon cancer could avoid the use of chemotherapy and be spared toxicities such as neuropathy: according to a study in which ctDNA liquid biopsy monitoring for the return of the disease was carried out.

Aan identifyable subset of patients with high-risk ER+ HER2- early breast cancer better off without chemotherapy

Antibody Drug Conjugate Prolongs Life in NSCLC refractory to EGFR TKI Therapy

ADC beats SOC in previously treated Advanced Breast Cancer

multi-cancer early detection (MCED) test

A new anti cancer drug sevabertinib, that targets mutated HER2, has proved effective in the SOHO-01 study among patients wiith HER2 mutated non small cell lung cancer. It has now been reported in the New England Journal of Medicine and at the European Society of Medical Oncology

A big step forwards in the management of muscle invasive bladder cancer in which platinum cannot be used has been taken in the KEYNOTE-905 study of perioperative antibody drug conjugate thereapy with immune checkpoint inhbition

A Chinese ADC and a western ADC slugged it out at the 2025 ESMO held in Berlin.

Tarlatamab, a bi-specific T-cell engager drug added to innitial immunochemotherapy brought encouraging initial survival outcomes in the DeLLphi-303 reported at the European Society for Medical Oncology 2025 Annual Congress in Berlin, Germany.

John P. Crown MD MBA: ESMO 2025, Berlin: Adjuvant Ribociclib Brought Longer Freedom from Metastases for Patients with HR+/HER2- Early Breast Cancer: NATALEE Five Year Outcomes

Javier Cortés tells his findings from ASCENT-03 as reported to ESMO 2025 in Berlin with antibody drug conjugate as initial therapy for TNBC in patients testing negative for PD-1/PD-L1

resectable-gastric-and-ge-junction adenocarcinoma-radiation-therapy-no-help

Domenica Lorusso MD PhD: Initial therapy with Pembrolizumab added to chemoradiotherapy boosts survival in high-risk locally advanced cervix cancer

James Larkin FRCP, PhD talks about the big changes in survival prospects for patients with advanced and metastatic melanoma that have take place over the last 10 years thanks to combination checkpoint inhibitor immunotherapy

The cancer prevention benefit of vaccination against the human papilloma virus cancer prevent are slowly accruing thanks to European, American and other population-based studies.  I’m Peter Goodwin with more cancer news from the Audio Journal of Oncology.  At the 2024 ASCO annual meeting in Chicago there was solid confirmatory evidence that HPV vaccination prevents cancer

Rebecca Dent surveys the most recent ESMO Annual Meeting to prepare our thoughts for the ESMO 2025 meeting

bart-neyns-md-phd-injectng-cells-into-cranial-cavity-for-recurrent-glioblastoma-long-survival

Victor E Velculescu MD PhD

Timothy Yap MD PhD MBBS selective PARP inhibitor promise in breast, ovarian, pancreatic, prostate tumors.

Stacey Kenfield and June Chan UCSF

Jonathan T Yang, MD, PhD

Heather McArthur MD MPH

Stefan Paepke MD

Sophie Bosma MD PhD

Adri Voogd PhD

Annemiek van Hemert MD PhD

Tim Rattay MBChB PhD

Partial breast irradiation, given before breast-conserving surgery, achieved durable pathologic complete remissions in low-risk breast cancer, and even held out the prospect of surgery-free treatment for some patients. 

Heather McArthur MD MPH

ImPrintTN single-sample classifier identifies no benefit from deoadjuvant pembroliozumab in TNBC

Patient Derived Organoids Shine a Light on Epigenetic Archetypes as Key Drivers of Cancer Drug Resistance LONDON, UK—How to stay ahead with treatment as cancer cells evolve to evade therapies and regimens coulld soon become a lot easier thanks to a new clarification of processes of cancer cell evolution that are not directly driven by DNA, but by the epigenetic processes that influence DNA expression. This is the message coming from research published in the journal Cancer Research by a group from the Institute of Cancer Research in London. The research promises to help doctors design individual protocols with a customised combination of agents that can be individualised not only for specificity ad efficacy but also in their sequencing and duration by refering to algothithms derived from the new knowledge of epigenetic cancer influencers.

Homologous Repair Deficient Triple Negative Breast Cancer Positive for BRCA1/2 Mutations Better with Neoadjuvant Olaparib + Carboplatin

HER2 Positive Advanced Breast Cancer ADC Combination Superior

Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09.

“Adjuvant nivolumab added to chemoradiotherapy after surgery provided a statistically and clinically meaningful disease-free survival improvement in PD-L1 all-comers patients. This is the first time in over two decades that a therapy demonstrated superiority over standard of care in patients with resected locally advanced squamous cell cancer of the head and neck at high risk of relapse.”

Luis G Paz-Ares MD PhD discdusses the addition of lurbinectedin as maintenance therapy for extensive stage small cell lung cancer (SCLC)

Yelena Y. Janjigian MD says that perioperative anti-PD-L1 immunotherapy with durvalumab was a "game changer" meriting use as a new standard of care when used together with chemotherapy to treat resectable gastric or gastroesophageal cancer. She made this announcement at the 2025 ASCO Plenary Session in Chicago

Exercise was as good as the addition of a drug among patients with high risk stage 2 or stage 3 colon cancer after curative surgery, extending life and preventing cancer recurrence. Christopher Booth says it should be incorporated and recommended as standard adjuvant therapy

Andy Zeng, Toronto: Transcriptome Map Key to Malignant Transformation in AML

Yelena Y Janjigian MD talks about the use of ctDNA to direct immunotherapy among patients with mismatch repair deficient solid tumors.

Paolo Marchetti MD, Scientific Director, Istituto Dermatopatico dell'Immacolata, Rome

The microbiome is emerging as a powerful ally to cancer doctors to harness in tandem with curative therapies, especially with allogeneic stem cell transplantation.

Bi-specific T-cell engager promise in B-cell acute lymphoblastic leukemia

BRIGHTON, UK—In underserved communities throughout the world low rates of early breast cancer detection are key drivers of mortality, according to the findings of research from Uganda, the United Kingdom and Nigeria. A range of low cost community-based interventions could be used to modify these drivers, the research concludes.

Amy A. Kirkwood MSc

Don't Delay Stem Cell Transplant For Patients with Relapsed or Refractory Acute Myeloid Leukemia

Audio Journal of Oncology September 9, 2022 By Peter M Goodwin PARIS, France—Particulate air pollution was identified as a key step in malignant transformation from benign DNA to non-small cell lung cancer according to a report delivered to the 2022 Congress of the European Society for Medical Oncology (ESMO). Charles Swanton FRCP BSc PhD, Professor […]

How Babies Use Object Permanence To Get What They Want 2022: A report from the journal: Pediatric Physical Therapy Regina Harbourne PhD, PT, PCS, FAPTA, Associate Professor in the Department of Physical Therapy at Rangos School of Health Sciences, in Duquesne University, Pittsburgh USA, talks about her group’s research investigating motor and cognitive development in […]

UK & NETHERLANDS—Following the the AJO Podcast interview with Professor Harry de Koning MD PhD, from the Erasmus University in Rotterdam, who discussed his research published in the New England Journal of Medicine that supports the widespread introduction of computed tomographic (CT) screening to detect lung cancer, this edition of the podcast hears from Professor […]

Second Study Confirms Lung Cancer CT Screening Cuts Deaths NETHERLANDS—Erasmus University Medical Center, Rotterdam—Research published in the New England Journal of Medicine has confirmed the viability of computed tomographic (CT) screening for detecting cases of lung cancer early in high-risk individuals—namely those who smoke heavily and or have done so for decades. A big new […]

  Audio Journal of Oncology   SAN DIEGO—The first-line treatment of choice for older patients with chronic lymphocytic leukemia (CLL) should now be single agent ibrutinib according to conclusions drawn from the Alliance North American Intergroup Study A041202 reported at the 2018 Annual Meeting of the American Society of Hematology (ASH). “Unless there is a […]

Microbiome Diversity Key To Survival After Allogeneic Hematopoietic Cell Transplantation The Audio Journal of Oncology Podcast SAN DIEGO—Overall survival after allogeneic hematopoietic cell transplantation (allo-HCT) was found to be adversely influenced by a lack of diversity in the intestinal microbiota—before, during and after the transplant—in a study from four research centers in three countries reported […]

January 2020 Pediatric Physical Therapy journal highlights the importance of non-billable tasks that are essential to achieving good outcomes. The authors describe how both direct and indirect patient tasks need to be included to achieve therapy goals

The “Beat AML” study assesses an algorithm screening for genomic features in order to choose appropriate targeted therapies for individual patients with their specific form of AML

SAN DIEGO—Patients 70 years old and younger with previously untreated chronic lymphocytic leukemia (CLL) lived longer and had progression of their disease delayed when treated with ibrutinib (an irreversible inhibitor of Bruton’s tyrosine kinase [BTK]) combined with the anti-CD 20 agent rituximab than patients in a control arm receiving standard fludarabine, cyclophosphamide and rituximab (FCR) […]

MUNICH—A “salutary lesson” was reported by researchers investigating therapy for oropharyngeal cancer at the 2018 annual congress of the European Society for Medical Oncology (ESMO). It came from results of the De-ESCALaTE HPVstudy that found patients with low-risk head and neck cancer who tested positive for human papilloma virus (HPV+) did better if they had […]

MUNICH—A leading European oncologist acknowledged the impressive life-extending potential of new drug combinations for metastatic renal cell carcinoma discussed at the 2018 annual congress of the European Society for Medical Oncology (ESMO). Progress was reported with purely immunological approaches—using two different programmed death ligand 1 (PD-L1) targeted immunotherapies together—and also with therapies combining immunotherapy with […]

MUNICH— A doubling of progression free survival (PFS) and objective response rate (ORR) was observed in patients who had their previously untreated advanced renal cell cancer (RCC) treated with a combination of the vascular endothelial growth factor (VEGF) inhibitor axitinib plus the anti-programmed death one ligand (PD-L1) avelumab in comparison with those receiving standard sunitinib […]

MUNICH— Anaplastic lymphoma kinase (ALK) inhibitors are as effective in “real world” clinical use for treating patients with non-small cell lung cancer (NSCLC) who test positive for ALK gene rearrangements as they are in clinical studies—even though randomized trials “cherry pick” patients to get statistically valid results. This is the conclusion of a retrospective analysis […]

MUNICH—The role of poly ADP ribose polymerase (PARP) inhibitors for treating newly diagnosed advanced ovarian cancer was under review at the 2018 annual congress of the European Society for Medical Oncology (ESMO) in the light of findings from the SOLO1 randomized phase three trial in which there was more than a doubling of the numbers […]

BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib MUNICH—An “unprecedented improvement” in progression free survival (PFS) was observed in the randomized controlled double-blind phase three SOLO1 study of women with newly diagnosed ovarian cancer who had BRCA1/2 mutations and were treated with the poly ADP ribose polymerase (PARP) inhibitor olaparib after their standard initial […]

MUNICH— Immunotherapy with the anti programmed death ligand 1 (PD-L1) checkpoint inhibitor atezolizumab in combination with nab-paclitaxel chemotherapy prolonged progression-free survival (PFS) among patients with metastatic triple-negative breast cancer in the randomized phase three IMpassion130 trial reported at the 2018 annual congress of the European Society for Medical Oncology, ESMO. https://www.nejm.org/doi/full/10.1056/NEJMoa1809615?query=featured_home The experimental treatment also […]

    MUNICH—A combination of the phosphoinositide 3-kinase (PI3K) inhibitor alpelisib plus fulvestrant significantly extended progression free survival (PFS) compared to placebo plus fulvestrant in patients with hormone receptor positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer in the randomized phase three SOLAR-1 trial reported at the 2018 annual congress of the European […]

MUNICH—Patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer who were treated with a combination of the cyclin dependent kinase (CDK) 4/6 inhibitor palbociclib in combination with fulvestrantlived longer than those receiving a placebo with fulvestrant in the prospective, randomized, double-blind, phase three PALOMA-3 study from which overall survival […]

MUNICH—More than four years median overall survival was reported in patients treated with an inhibitor of anaplastic lymphoma kinase (ALK) for their ALK gene rearranged non-small cell lung cancer (NSCLC) in a single-arm phase two study reported at the 2018 annual congress of the European Society for Medical Oncology, ESMO. http://212.114.167.162/slidecenter/esmo2018/attendee/confcal/session/calendar?q=felip “The information presented here […]

A negative finding with pembrolizumab points to caution in molecular cancer targeting

BARCELONA—Oral cabozantinib “significantly improved” overall survival (OS) and progression free survival (PFS) compared to placebo in patients with advanced hepatocellular carcinoma(HCC) whose disease had progressed despite sorafenib therapy in the phase 3 CELESTIAL trial reported to the 2018 ESMO World Congress on Gastrointesinal Cancer. http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.207 “This is a new oral drug [that’s] very easy for […]

BARCELONA—A chemotherapy combination consisting of trifluridine with tipiracil showed a “clinically meaningful and statistically significant” improvement in overall survival (OS) and progression free survival (PFS) compared with placebo in patients with heavily-pretreated metastatic gastric cancer (mGC) refractory to standard therapies in the randomized phase three TAGS study reported at the ESMO 20th World Congress on […]

CHICAGO—A 25 per cent risk reduction for esophageal cancer was found to be associated with prophylactic therapy consisting of a proton pump inhibitor (PPI) and aspirin in the phase three randomized ASPECT multicenter study from the United Kingdom reported at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO). The trial investigated […]

CHICAGO—Patients with resectable and “borderline resectable” pancreatic cancers treated with chemoradiation before surgery (followed by adjuvant chemotherapy) had significantly improved outcomes compared to those randomized to have surgery first and adjuvant chemotherapy in the Dutch Pancreatic Cancer Group’sPREOPANC-1 randomized, controlled, multicenter phase III trialreported at the 2018 Annual Meeting of the American Society of Clinical […]

CHICAGO—Patients with newly-diagnosed hormone-sensitive metastatic prostate cancer (mPC) who had prostate radiotherapy (RT) before their androgen deprivation therapy (ADT) lived longer than those treated with standard ADT alone in a retrospective analysis—the largest single-center experience to date of primary tumor-directed RT in mPC—reported to the 2018 Annual Meeting of the American Society of Clinical Oncology […]

CHICAGO—Clinically targetable mutations were identified and patient subgroups pinpointed by whole genome sampling (WGS) of castration-resistant metastatic prostate cancer (mPC) in a study reportedatthe 2018 Annual Meeting of the American Society of Clinical Oncology. (https://meetinglibrary.asco.org/record/160671/abstract) Lisanne F van Dessel MD, a medical oncologist at Erasmus Medical Center Cancer Institute in Rotterdam, The Netherlands, tells the […]

CHICAGO—A gene test that predicts for relapse in women with estrogen receptor positive early breast cancer can identify patients with low-risk disease who could safely avoid extending their endocrine therapy beyond the standard five years, according to study findings reported in a poster session at the 2018 Annual Meeting of the American Society of Clinical […]

CHICAGO—Men who had breast-conserving therapy (BCT) including radiation for their early breast cancer lived longer than those who had total or partial mastectomy—with or without radiation—in findings from a large retrospective survey of male breast cancer reported at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO). https://meetinglibrary.asco.org/record/162945/abstract In a poster presentation […]

CHICAGO—A “cluster randomized controlled trial” of treatment for patients with advanced cancers found that the use of standardized geriatric assessments significantly increased the number and quality of discussions about age-related concerns in comparison with usual care and also resulted in higher scores of patient satisfaction—which the investigators regarded as paramount among therapy outcomes. (https://meetinglibrary.asco.org/record/159519/abstract) In […]

CHICAGO—Women and men were treated differently for the same tumor stages of head and neck cancer (HNC) and had different outcomes in a study with patients surveyed over a fifteen-year period in Santa Clara, California. The findings—using the generalized competing event (GCE) assessment model that balanced the risk of cancer death against non-cancer death—has prompted […]

CHICAGO, IL—Patients whose non-small cell lung cancers (NSCLC) expressed more than one per cent of the programmed death ligand-1 (PD-L1) tumor proportion score (TPS) lived longer when treated with the anti programmed death 1 (PD-1) antibody pembrolizumab than a control group of patients receiving platinum-based chemotherapy in the open-label, phase three KEYNOTE-042 study reported at […]

CHICAGO—Prophylactic contralateral (CLT) breast radiotherapy was associated with significantly fewer and delayed cases of breast cancer in women having standard therapy for their ipsilateral BRCA mutation-associated breast cancers in a study from Israel reported in a poster session at the American Society of Clinical Oncology 2018 annual meeting. https://meetinglibrary.asco.org/record/161629/abstract (Phase II national clinical trial of […]

BARCELONA—Handgrip strength (HGS) was found to be an independent quantitative marker for overall survival among patients with early-stage non-small cell lung cancer (NSCLC) being treated with stereotactic body radiotherapy (SBRT) in a study discussed at the 2018 European Society for Radiotherapy & Oncology (ESTRO 37) conference. ABSTRACT: PV-0041 Hand grip strength: independent prognostic selection test […]

BARCELONA—Accelerated partial breast irradiation (ABPI) brachytherapy completed in a single week gave at least as good efficacy and safety as other radiotherapy protocols after breast-conserving therapy (BCS) for patients with low-risk breast cancer and brought advantages in terms of symptoms and convenience in a randomized phase three trial(conducted at 16 European medical centers)reported at the […]

BARCELONA—Image-guided adaptive brachytherapy (IGABT) for patients with cervical cancer did not increase risk for ureteral stricture (a rare but feared complication of pelvic radiotherapy) in European research reported at the European Society for Radiotherapy & Oncology (ESTRO 37) 2018 conference. (OC-0072 Risk factors for ureteral stricture after IGABT in cervical cancer: results from the EMBRACE […]

BARCELONA—It is essential to conduct a comprehensive geriatric assessment of patients over 74 with lung cancer before deciding to escalate treatment dose by switching to concurrent chemo-radiotherapy in an attempt to improve outcomes. This was the conclusion of a phase 2 study reported at the European Society for Radiotherapy & Oncology (ESTRO 37) conference. (PV-0039 […]

BARCELONA—The accuracy of radiation targeting using image-guided radiotherapy (IGRT) was significantly associated with overall survival in a study of a large cohort of patients treated with IGRT for their lung and esophageal cancers. reported at the 2018 European Society For Radiotherapy and Oncology (ESTRO 37) annual conference (ABSTRACT OC-0322, “Residual setup errors after IGRT are […]

BARCELONA—Women who develop breast symptoms—especially lumps—between regular mammography screening examinations are up to four times more likely to have a diagnosis of breast cancer soon after than women who do not have symptoms according to findings of a massive study of routine mammography from Finland reported at the 2018 European Breast Cancer Conference (EBCC 11). […]